Arthur Portnow
Cardiovascular Disease · Sarasota, FLNPI 1952347635
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,031 and has fallen 98.7% since, to $14 in 2022. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 180 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$373
- AstraZeneca$332
- GSK$307
- Astellas Pharma US Inc$283
- AbbVie$238
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$198
- plus $1K from 12 others
What the payments were for
- Food & beverage$2,54193%
- Education$2007%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 28 | $373 |
| AstraZeneca | 24 | $332 |
| GSK | 25 | $307 |
| Astellas Pharma US Inc | 13 | $283 |
| AbbVie(2 entities) | 13 | $238 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $198 |
| Avanir Pharmaceuticals, Inc. | 9 | $160 |
| Merck | 8 | $154 |
| Lilly USA, LLC | 9 | $124 |
| Sanofi-aventis U.S. LLC | 6 | $112 |
| Boehringer Ingelheim | 8 | $107 |
| Amgen | 7 | $106 |
| Novo Nordisk | 4 | $69 |
| Johnson & Johnson | 3 | $48 |
| Genentech USA, Inc. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
How this compares
$2,741 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Sarasota
- Manfouz El ShahawySarasota$116K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.